Steinbrook R: Controlling conflict of interest -- Proposals from the Institute of Medicine. N Engl J Med. 2009, 360 (21): 2160-2163.
Article
PubMed
CAS
Google Scholar
Wang AT, McCoy CP, Murad MH, Montori VM: Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ. 2010, 340 (mar18_1): c1344-
Article
PubMed
PubMed Central
Google Scholar
Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA: Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry. 2005, 162 (10): 1957-1960.
Article
PubMed
Google Scholar
Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality. systematic review. BMJ. 2003, 326 (7400): 1167-1170.
PubMed
Google Scholar
Sismondo S: Pharmaceutical company funding and its consequences: A qualitative systematic review. Contemporary Clinical Trials. 2008, 29 (2): 109-113.
Article
PubMed
Google Scholar
Bourgeois FT, Murthy S, Mandl KD: Outcome reporting among drug trials registered in ClinicalTrials.gov. Annals of Internal Medicine. 2010, 153 (3): 158-166.
Article
PubMed
PubMed Central
Google Scholar
Blum JA, Freeman K, Dart RC, Cooper RJ: Requirements and definitions in conflict of interest policies of medical journals. JAMA. 2009, 302 (20): 2230-2234.
Article
PubMed
CAS
Google Scholar
Licurse A, Barber E, Joffe S, Gross C: The impact of disclosing financial ties in research and clinical care: A systematic review. Arch Intern Med. 2010, 170 (8): 675-682.
Article
PubMed
Google Scholar
Chaudhry S: Does declaration of competing interests affect readers' perceptions? A randomised trial. BMJ. 2002, 325 (7377): 1391-1392.
Article
PubMed
PubMed Central
Google Scholar
Schroter S, Morris J, Chaudhry S, Smith R, Barratt H: Does the type of competing interest statement affect readers' perceptions of the credibility of research? Randomised trial. BMJ. 2004, 328 (7442): 742-743.
Article
PubMed
PubMed Central
Google Scholar
Goodwin R, Mullan B: Trust not in money: The effect of financial conflict of interest disclosure on dietary behavioural intention. British Food Journal. 2009, 111 (5): 408-420.
Article
Google Scholar
Lee KP, Schotland M, Bacchetti P, Bero LA: Association of journal quality indicators with methodological quality of clinical research articles. JAMA. 2002, 287 (21): 2805-2808.
Article
PubMed
Google Scholar
Carlat D: Dr. Drug Rep [Internet]. 2007, The New York Times, [cited 2010 Aug 12], [http://www.nytimes.com/2007/11/25/magazine/25memoir-t.html]
Google Scholar
Meffert JJ: Key opinion leaders where they come from and how that affects the drugs you prescribe. Dermatologic Therapy. 2009, 22 (3): 262-268.
Article
PubMed
Google Scholar
Fava GA: Should the drug industry work with key opinion leaders? No. BMJ. 2008, 336 (7658): 1405-
Article
PubMed
PubMed Central
Google Scholar
Moynihan R: Key opinion leaders: independent experts or drug representatives in disguise?. BMJ. 2008, 336 (7658): 1402-1403.
Article
PubMed
PubMed Central
Google Scholar
Moffatt B, Elliott C: Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspect. Biol. Med. 2007, 50 (1): 18-31.
Article
PubMed
Google Scholar
Fugh-Berman AJ, Dodgson SJ: Ethical considerations of publication planning in the pharmaceutical industry. Open Medicine. 2008, 2 (4):
Lacasse JR, Leo J: Ghostwriting at elite academic medical centers in the United States. PLoS Med. 2010, 7 (2): e1000230-
Article
PubMed
PubMed Central
Google Scholar
Sismondo S: Ghost management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry?. PLoS Med. 2007, 4 (9): e286-
Article
PubMed
PubMed Central
Google Scholar
Jureidini JN, McHenry LB, Mansfield PR: Clinical trials and drug promotion: Selective reporting of study 329. The International Journal of Risk and Safety in Medicine. 2008, 20 (1): 73-81.
Google Scholar
Healy D, Cattell D: Interface between authorship, industry and science in the domain of therapeutics. The British Journal of Psychiatry. 2003, 183 (1): 22-27.
Article
PubMed
Google Scholar
Healy D: Manufacturing consensus. Cult Med Psychiatry. 2006, 30 (2): 135-156.
Article
PubMed
Google Scholar
Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B: Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001, 40 (7): 762-772.
Article
PubMed
CAS
Google Scholar
Berenson A: Evidence in Vioxx suits shows intervention by Merck officials [Internet]. 2005, The New York Times, [cited 2009 Dec 24], [http://www.nytimes.com/2005/04/24/business/24drug.html?_r=1]
Google Scholar
Ross JS, Hill KP, Egilman DS, Krumholz HM: Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008, 299 (15): 1800-1812.
Article
PubMed
CAS
Google Scholar
Kaiser J: Senate probe of research psychiatrists. Science. 2009, 325 (5936): 28-30.
Article
PubMed
CAS
Google Scholar
Smith RE, Vogt CA: The effects of integrating advertising and negative word-of-mouth communications on message processing and response. Journal of Consumer Psychology. 1995, 4 (2): 133-151.
Article
Google Scholar
Hunt JM, Kernan JB: The role of disconfirmed expectancies in the processing of advertising messages. Journal of Social Psychology. 1984, 124 (2): 227-
Article
Google Scholar
Faul F, Erdfelder E, Lang A, Buchner A: G*Power 3. 2006
Google Scholar
Rothman KJ, Greenland S, Lash TL: Modern Epidemiology. 2008, Lippincott Williams & Wilkins, Third
Google Scholar
Frewer LJ, Howard C, Hedderley D, Shepherd R: What determines trust in information about food-related risks? Underlying psychological constructs. Risk Anal. 1996, 16 (4): 473-486.
Article
PubMed
CAS
Google Scholar
Wadman M: Spitzer sues drug giant for deceiving doctors. Nature. 2004, 429 (6992): 589-
Article
PubMed
CAS
Google Scholar
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R: Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008, 358 (3): 252-260.
Article
PubMed
CAS
Google Scholar
Steinman MA, Bero LA, Chren M, Landefeld CS: Narrative Review: The promotion of Gabapentin: An analysis of internal industry documents. Annals of Internal Medicine. 2006, 145 (4): 284-293.
Article
PubMed
Google Scholar
Hughes V: Sunshine on conflicts. Nat Biotech. 2010, 28 (7): 641-643.
Article
CAS
Google Scholar
Murray S, Brophy J, Palepu A: Open Medicine's ghost and guest authorship policy. Open Med. 2010, 4 (1): e11-e12.
PubMed
PubMed Central
Google Scholar
Grassley C: Ghostwriting in the medical literature [Internet]. [http://grassley.senate.gov/about/upload/Senator-Grassley-Report.pdf]
Kumkale GT, Albarracín D: The sleeper effect in persuasion: A meta-analytic review. Psychological Bulletin. 2004, 130 (1): 143-172.
Article
PubMed
PubMed Central
Google Scholar